CPT1A and acute myeloid leukemia: Indeed, heightened levels of NDUFA6, NDUFC1, SDHA, CYB5A, SLC25A12, ETFB and CPT1A were associated with poor EFS in AML patients (Table 1), Next, we sought to validate the prognostic value of the above-mentioned mitochondrial/OXPHOS mediators for AML patients utilizing the Gene Expression Profiling Interactive Analysis (GEPIA) tool [37].